ZURICH (Reuters) – Roche said on Friday its gantenerumab antibody had received breakthrough therapy designation from the U.S. Food and Drug Administration for the treatment of Alzheimer’s disease.
The Swiss pharmaceutical giant said in a statement it expected further data on an ongoing Phase III study in the second half of 2022.
(Reporting by Brenna Hughes Neghaiwi; Editing by Edmund Blair)
